A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Clinical trial NCT07000344 · TERMINATED
Trial details
- NCT number
- NCT07000344
- Sponsor
- Peking Union Medical College Hospital
- Status
- TERMINATED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2026-03-29
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.